The First Affiliated Hospital, Zhejiang University School of Medicine
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 2,500
- Locations
- 1
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 5 Years to 90 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age ≥ 5 years
- •First allo-HSCT from matched related, unrelated, or haploidentical donors
- •Achievement of complete remission after allo-HSCT
- •Donor blood sample collection before granulocyte colony-stimulating factor mobilization
- •Exclusion Criteria
- •Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia
- •Failure to achieve engraftment with full donor chimerism after allo-HSCT
- •Inability to extract DNA for telomere length analysis.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Overall survival
Time Frame: From date of transplantuntil the date of death from any cause, assessed up to 60 months.
The duration from transplant until death resulted from any cause.
Secondary Outcomes
- Relapse-free survival(From date of transplant until the date of relapse or death from any cause, assessed up to 60 months.)
- Cumulative incidence of relapse(From date of transplant until the date of relapse, assessed up to 60 months.)
Investigators
He Huang
The President of the First Affiliated Hospital, Zhejiang University School of Medicine
Zhejiang University